NEW YORK – Bellicum Pharmaceuticals said on Monday that the US Food and Drug Administration has accepted its investigational new drug application for its CAR T cell therapy, BPX-603, allowing it to proceed with human clinical trials.
Bellicum plans to initiate a Phase I/II trial of BPX-603 in patients with HER2-positive solid tumors later this year.